Intravenously administered nanoparticles increase survival following blast trauma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 28, 2014, Pages 10293-10298

  Lashof Sullivan, Margaret M ^a   Shoffstall, Erin ^a   Atkins, Kristyn T ^a   Keane, Nickolas ^b   Bir, Cynthia ^b   VandeVord, Pamela ^c   Lavik, Erin B ^a  

^a Case Western Reserve University   (United States)

^b Wayne State University   (United States)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Clot; Lung; Medic; Polytrauma; Synthetic platelets

Indexed keywords

HEMOSTATIC AGENT; HEMOSTATIC NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLAST INJURY; BLEEDING; CONTROLLED STUDY; DISEASE COURSE; LETHALITY; LUNG INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

CLOT; LUNG; MEDIC; POLYTRAUMA; SYNTHETIC PLATELETS;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BLAST INJURIES; DISEASE MODELS, ANIMAL; HEMORRHAGE; HEMOSTATICS; MALE; MICE; NANOPARTICLES; TIME FACTORS; WAR;

EID: 84904291832     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1406979111     Document Type: Article

References (29)

1. Champion HR, Bellamy RF, Roberts CP, Leppaniemi A (2003) A profile of combat injury. J Trauma 54(5, Suppl):S13-S19. (Pubitemid 36758844)
2. Krug EG, Sharma GK, Lozano R (2000) The global burden of injuries. Am J Public Health 90(4):523-526. (Pubitemid 30167408)
3. Regel G, Stalp M, Lehmann U, Seekamp A (1997) Prehospital care, importance of early intervention on outcome. Acta Anaesthesiol Scand Suppl 110:71-76.
4. Eastridge BJ, et al. (2012) Death on the battlefield (2001-2011): Implications for the future of combat casualty care. J Trauma Acute Care Surg 73(6, Suppl 5):S431-S437.
5. Warden D (2006) Military TBI during the Iraq and Afghanistan wars. J Head Trauma Rehabil 21(5):398-402.
6. Kauvar DS, Lefering R, Wade CE (2006) Impact of hemorrhage on trauma outcome: An overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma 60(6, Suppl):S3-S11.
7. Malone DL, et al. (2003) Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 54(5):898-905.
8. Ketchum L, Hess JR, Hiippala S (2006) Indications for early fresh-frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma 60(6, Suppl):S51-S58.
9. Coller BS, et al. (1992) Thromboerythrocytes: In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 89(2):546-555.
10. Levi M, et al. (1999) Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 5(1):107-111. (Pubitemid 29051007)
11. Fitzpatrick G, Vibhudatta A, Agashe H, Dee J (2010) Trehalose-stabilized freeze-dried human platelets, Thrombosomes, reduce blood loss in thrombocytopenic rabbit ear bleed model by as much as 89.5%. Vox Sang 99(Suppl 1):261.
12. Fitzpatrick GM, Cliff R, Tandon N (2013) Thrombosomes: A platelet-derived hemostatic agent for control of noncompressible hemorrhage. Transfusion 53(Suppl 1):100S-106S.
13. Modery-Pawlowski CL, Tian LL, Ravikumar M, Wong TL, Sen Gupta A (2013) In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct. Biomaterials 34(12):3031-3041.
14. Okamura Y, et al. (2005) Hemostatic effects of phospholipid vesicles carrying fibrinogen gamma chain dodecapeptide in vitro and in vivo. Bioconjug Chem 16(6):1589-1596. (Pubitemid 41681527)
15. Okamura Y, et al. (2010) Visualization of liposomes carrying fibrinogen gamma-chain dodecapeptide accumulated to sites of vascular injury using computed tomography. Nanomedicine (Lond Print) 6(2):391-396.
16. Benharash P, Bongard F, Putnam B (2005) Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients. Am Surg 71(9):776-780.
17. Martinowitz U, Zaarur M, Yaron BL, Blumenfeld A, Martonovits G (2004) Treating traumatic bleeding in a combat setting: Possible role of recombinant activated factor VII. Mil Med 169(12, Suppl):16-8, 4.
18. Bertram JP, et al. (2009) Intravenous hemostat: Nanotechnology to halt bleeding. Sci Transl Med 1(11):11ra22.
19. Shoffstall AJ, et al. (2012) Intravenous hemostatic nanoparticles increase survival following blunt trauma injury. Biomacromolecules 13(11):3850-3857.
20. Shoffstall AJ, et al. (2013) Tuning ligand density on intravenous hemostatic nanoparticles dramatically increases survival following blunt trauma. Biomacromolecules 14(8):2790-2797.
21. Monien BH, Cheang KI, Desai UR (2005) Mechanism of poly(acrylic acid) acceleration of antithrombin inhibition of thrombin: Implications for the design of novel heparin mimics. J Med Chem 48(16):5360-5368. (Pubitemid 41113920)
22. Mayorga MA (1997) The pathology of primary blast overpressure injury. Toxicology 121(1):17-28. (Pubitemid 27259671)
23. DePalma RG, Burris DG, Champion HR, Hodgson MJ (2005) Blast injuries. N Engl J Med 352(13):1335-1342.
24. Elsayed NM (1997) Toxicology of blast overpressure. Toxicology 121(1):1-15.
25. Wightman JM, Gladish SL (2001) Explosions and blast injuries. Ann Emerg Med 37(6):664-678. (Pubitemid 32521688)
26. Bertram JP, et al. (2009) Functionalized poly(lactic-co-glycolic acid) enhances drug delivery and provides chemical moieties for surface engineering while preserving biocompatibility. Acta Biomater 5(8):2860-2871.
27. Hermanson G (1996) Bioconjugate Techniques (Academic Press, San Diego), pp xxv, 785.
28. Cheng J, et al. (2007) Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5):869-876. (Pubitemid 44667020)
29. D'Addio SM, et al. (2010) Novel method for concentrating and drying polymeric nanoparticles: Hydrogen bonding coacervate precipitation. Mol Pharm 7(2):557-564.